Using Proteomics to Advance Drug Development – Translating Proteomics Episode 14

Chapters

00:00 – 01:06 – Introduction
01:06 – 06:51 – Proteomics in pre-clinical studies
06:51 – 11:40 – The importance of choosing the right model for preclinical work
11:40 – 17:10 – How proteomics is used in Phase I/II clinical trials
17:10 – 19:29 – Proteomics tools in patient selection
19:29 – 24:33 – Useful information that we get from proteomics that we can’t get from genomics or transcriptomics
24:33 – 28:14 – Proteomics in Phase III clinical trials and picking the best indications of drug efficacy
28:14 – 29:19 – Understanding why clinical trials fail
29:19 – End – Outro

Resources

• The National Cancer Institute’s webpage covering how clinical trials work
• Preprint on the miBrain model – An example of a new in vitro brain model
• Wasko et al., 2024 – Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer
• Geary et al., 2021 – Discovery and Evaluation of Protein Biomarkers as a Signature of Wellness in Late-Stage Cancer Patients in Early Phase Clinical Trials
• The NCI-MATCH trail: Lessons for precision oncology – Report on a large-scale trial using genomic biomarkers to match cancer patients to treatments
• Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer – Study using proteomics to understand mechanisms of resistance to a cancer drug

Find this episode on Apple Podcasts, Spotify, or YouTube.

Browse all episodes of Translating Proteomics.

Read our preprint to explore novel proteoform data and its potential in drug development.